Archives for 

AbbVie v. Amgen (adalimumab)

BPCIA Litigation Roundup (Midwinter 2017)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Genentech v. Amgen (bevacizumab)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News
Below is our midwinter update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly updates (Summer 2016, […]

View More

YEAR IN REVIEW: THE TOP-FIVE U.S. MARKET DEVELOPMENTS OF 2016

AbbVie v. Amgen (adalimumab)  •  Amgen v. Hospira (epoetin alfa)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. FDA News
Here are our picks for the top-five most significant U.S. market developments in the world of biosimilars in 2016: The FDA approved three biosimilar products in 2016, compared to only one in 2015 — Sandoz’s Zarxio®, a […]

View More

BPCIA Litigation Roundup (Fall 2016)

AbbVie v. Amgen (adalimumab)  •  Amgen v. Apotex (pegfilgrastim)  •  Amgen v. Hospira (epoetin alfa)  •  Amgen v. Sandoz (filgrastim)  •  Amgen v. Sandoz (pegfilgrastim)  •  Immunex v. Sandoz (etanercept)  •  Janssen v. Celltrion (infliximab)  •  U.S. Biosimilar Litigation News
Below is our Fall 2016 update on the U.S. patent litigations concerning proposed or approved biosimilar products. For additional details, please consult our BPCIA Litigation Summary Chart or our previous quarterly update (Summer […]

View More